(ATEZOLACC) Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer (37) NCT03612791. This evidence concerns the gene CD274 and cervical cancer.